nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—pancreatic cancer—stomach cancer	0.408	1	CtDrD
Erlotinib—EGFR—stomach cancer	0.125	0.758	CbGaD
Erlotinib—EGFR—Docetaxel—stomach cancer	0.0438	0.189	CbGbCtD
Erlotinib—NR1I2—Docetaxel—stomach cancer	0.0399	0.172	CbGbCtD
Erlotinib—ALB—stomach cancer	0.0398	0.242	CbGaD
Erlotinib—UGT1A1—Irinotecan—stomach cancer	0.018	0.0776	CbGbCtD
Erlotinib—CYP1B1—Docetaxel—stomach cancer	0.0152	0.0658	CbGbCtD
Erlotinib—ABCB1—Mitomycin—stomach cancer	0.0139	0.06	CbGbCtD
Erlotinib—CYP1B1—Doxorubicin—stomach cancer	0.0114	0.049	CbGbCtD
Erlotinib—ABCG2—Irinotecan—stomach cancer	0.00988	0.0427	CbGbCtD
Erlotinib—ABCG2—Fluorouracil—stomach cancer	0.00948	0.0409	CbGbCtD
Erlotinib—ABCG2—Docetaxel—stomach cancer	0.00724	0.0313	CbGbCtD
Erlotinib—ALB—Irinotecan—stomach cancer	0.00681	0.0294	CbGbCtD
Erlotinib—ALB—Fluorouracil—stomach cancer	0.00653	0.0282	CbGbCtD
Erlotinib—CYP3A5—Irinotecan—stomach cancer	0.00547	0.0236	CbGbCtD
Erlotinib—ABCG2—Doxorubicin—stomach cancer	0.0054	0.0233	CbGbCtD
Erlotinib—ABCG2—Methotrexate—stomach cancer	0.00523	0.0226	CbGbCtD
Erlotinib—CYP2C8—Fluorouracil—stomach cancer	0.00505	0.0218	CbGbCtD
Erlotinib—CYP3A5—Docetaxel—stomach cancer	0.00401	0.0173	CbGbCtD
Erlotinib—CYP1A2—Fluorouracil—stomach cancer	0.00391	0.0169	CbGbCtD
Erlotinib—ALB—Methotrexate—stomach cancer	0.0036	0.0156	CbGbCtD
Erlotinib—ABCB1—Irinotecan—stomach cancer	0.00356	0.0154	CbGbCtD
Erlotinib—ABCB1—Docetaxel—stomach cancer	0.00261	0.0113	CbGbCtD
Erlotinib—CYP3A4—Irinotecan—stomach cancer	0.00213	0.00922	CbGbCtD
Erlotinib—ORM1—bile—stomach cancer	0.00206	0.0569	CbGeAlD
Erlotinib—ABCB1—Doxorubicin—stomach cancer	0.00195	0.0084	CbGbCtD
Erlotinib—ABCB1—Methotrexate—stomach cancer	0.00188	0.00814	CbGbCtD
Erlotinib—CYP2D6—Doxorubicin—stomach cancer	0.00183	0.00792	CbGbCtD
Erlotinib—CYP3A4—Docetaxel—stomach cancer	0.00156	0.00675	CbGbCtD
Erlotinib—CYP3A4—Doxorubicin—stomach cancer	0.00117	0.00504	CbGbCtD
Erlotinib—Vandetanib—FYN—stomach cancer	0.000951	0.375	CrCbGaD
Erlotinib—JAK3—hematopoietic system—stomach cancer	0.000844	0.0234	CbGeAlD
Erlotinib—NR1I2—digestive system—stomach cancer	0.000735	0.0203	CbGeAlD
Erlotinib—ABL1—Topotecan—Irinotecan—stomach cancer	0.000698	0.424	CbGdCrCtD
Erlotinib—FLT3—hematopoietic system—stomach cancer	0.000666	0.0184	CbGeAlD
Erlotinib—Gefitinib—CHEK2—stomach cancer	0.000614	0.242	CrCbGaD
Erlotinib—HIPK4—endocrine gland—stomach cancer	0.000614	0.017	CbGeAlD
Erlotinib—NR1I2—endocrine gland—stomach cancer	0.000607	0.0168	CbGeAlD
Erlotinib—JAK3—lymphoid tissue—stomach cancer	0.000594	0.0165	CbGeAlD
Erlotinib—JAK3—digestive system—stomach cancer	0.000587	0.0163	CbGeAlD
Erlotinib—ULK3—hematopoietic system—stomach cancer	0.000574	0.0159	CbGeAlD
Erlotinib—ORM1—gall bladder—stomach cancer	0.00057	0.0158	CbGeAlD
Erlotinib—NR1I2—liver—stomach cancer	0.000547	0.0152	CbGeAlD
Erlotinib—MKNK1—hematopoietic system—stomach cancer	0.000541	0.015	CbGeAlD
Erlotinib—AURKC—endocrine gland—stomach cancer	0.000524	0.0145	CbGeAlD
Erlotinib—ALB—gall bladder—stomach cancer	0.0005	0.0139	CbGeAlD
Erlotinib—PIP4K2C—pancreas—stomach cancer	0.00049	0.0136	CbGeAlD
Erlotinib—EPHA6—endocrine gland—stomach cancer	0.000485	0.0134	CbGeAlD
Erlotinib—JAK3—endocrine gland—stomach cancer	0.000485	0.0134	CbGeAlD
Erlotinib—FLT3—lymphoid tissue—stomach cancer	0.000469	0.013	CbGeAlD
Erlotinib—TNK1—endocrine gland—stomach cancer	0.000445	0.0123	CbGeAlD
Erlotinib—STK10—hematopoietic system—stomach cancer	0.000445	0.0123	CbGeAlD
Erlotinib—FLT3—bone marrow—stomach cancer	0.000427	0.0118	CbGeAlD
Erlotinib—UGT1A1—hematopoietic system—stomach cancer	0.00042	0.0116	CbGeAlD
Erlotinib—LTK—lymph node—stomach cancer	0.00042	0.0116	CbGeAlD
Erlotinib—SLK—pancreas—stomach cancer	0.000417	0.0115	CbGeAlD
Erlotinib—TNK1—liver—stomach cancer	0.000402	0.0111	CbGeAlD
Erlotinib—ULK3—digestive system—stomach cancer	0.0004	0.0111	CbGeAlD
Erlotinib—PIP4K2C—bone marrow—stomach cancer	0.000386	0.0107	CbGeAlD
Erlotinib—FLT3—endocrine gland—stomach cancer	0.000383	0.0106	CbGeAlD
Erlotinib—MKNK1—lymphoid tissue—stomach cancer	0.000381	0.0105	CbGeAlD
Erlotinib—MKNK1—digestive system—stomach cancer	0.000376	0.0104	CbGeAlD
Erlotinib—ULK3—bone marrow—stomach cancer	0.000368	0.0102	CbGeAlD
Erlotinib—AURKC—lymph node—stomach cancer	0.000362	0.01	CbGeAlD
Erlotinib—MKNK1—bone marrow—stomach cancer	0.000347	0.0096	CbGeAlD
Erlotinib—PIP4K2C—endocrine gland—stomach cancer	0.000346	0.00958	CbGeAlD
Erlotinib—FLT3—liver—stomach cancer	0.000345	0.00956	CbGeAlD
Erlotinib—JAK3—lymph node—stomach cancer	0.000335	0.00929	CbGeAlD
Erlotinib—ULK3—endocrine gland—stomach cancer	0.00033	0.00914	CbGeAlD
Erlotinib—ABL2—liver—stomach cancer	0.000329	0.00913	CbGeAlD
Erlotinib—SLK—bone marrow—stomach cancer	0.000328	0.00909	CbGeAlD
Erlotinib—ORM1—hematopoietic system—stomach cancer	0.000323	0.00894	CbGeAlD
Erlotinib—EGFR—liver—stomach cancer	0.000322	0.00891	CbGeAlD
Erlotinib—STK10—lymphoid tissue—stomach cancer	0.000313	0.00868	CbGeAlD
Erlotinib—PIP4K2C—liver—stomach cancer	0.000312	0.00863	CbGeAlD
Erlotinib—MKNK1—endocrine gland—stomach cancer	0.000311	0.00861	CbGeAlD
Erlotinib—STK10—digestive system—stomach cancer	0.00031	0.00858	CbGeAlD
Erlotinib—SLCO2B1—hematopoietic system—stomach cancer	0.000309	0.00857	CbGeAlD
Erlotinib—TNK1—lymph node—stomach cancer	0.000308	0.00853	CbGeAlD
Erlotinib—ABL1—hematopoietic system—stomach cancer	0.000307	0.0085	CbGeAlD
Erlotinib—Vandetanib—VEGFA—stomach cancer	0.000306	0.121	CrCbGaD
Erlotinib—ULK3—liver—stomach cancer	0.000298	0.00824	CbGeAlD
Erlotinib—UGT1A1—digestive system—stomach cancer	0.000292	0.0081	CbGeAlD
Erlotinib—STK10—bone marrow—stomach cancer	0.000285	0.00791	CbGeAlD
Erlotinib—MKNK1—liver—stomach cancer	0.00028	0.00776	CbGeAlD
Erlotinib—ABL1—smooth muscle tissue—stomach cancer	0.00027	0.00748	CbGeAlD
Erlotinib—SLK—liver—stomach cancer	0.000265	0.00735	CbGeAlD
Erlotinib—FLT3—lymph node—stomach cancer	0.000265	0.00733	CbGeAlD
Erlotinib—CYP1B1—hematopoietic system—stomach cancer	0.00026	0.0072	CbGeAlD
Erlotinib—Vandetanib—EGFR—stomach cancer	0.000258	0.102	CrCbGaD
Erlotinib—STK10—endocrine gland—stomach cancer	0.000256	0.00709	CbGeAlD
Erlotinib—ABL2—lymph node—stomach cancer	0.000253	0.007	CbGeAlD
Erlotinib—ABL1—pancreas—stomach cancer	0.00025	0.00692	CbGeAlD
Erlotinib—EGFR—lymph node—stomach cancer	0.000247	0.00683	CbGeAlD
Erlotinib—Gefitinib—EGFR—stomach cancer	0.000245	0.0968	CrCbGaD
Erlotinib—UGT1A1—endocrine gland—stomach cancer	0.000242	0.00669	CbGeAlD
Erlotinib—PIP4K2C—lymph node—stomach cancer	0.000239	0.00662	CbGeAlD
Erlotinib—STK10—liver—stomach cancer	0.000231	0.00639	CbGeAlD
Erlotinib—CYP1B1—smooth muscle tissue—stomach cancer	0.000229	0.00634	CbGeAlD
Erlotinib—MAP2K5—endocrine gland—stomach cancer	0.000228	0.00633	CbGeAlD
Erlotinib—ULK3—lymph node—stomach cancer	0.000228	0.00632	CbGeAlD
Erlotinib—UGT1A1—liver—stomach cancer	0.000218	0.00603	CbGeAlD
Erlotinib—ABL1—lymphoid tissue—stomach cancer	0.000216	0.00598	CbGeAlD
Erlotinib—SLCO2B1—digestive system—stomach cancer	0.000215	0.00596	CbGeAlD
Erlotinib—MKNK1—lymph node—stomach cancer	0.000215	0.00595	CbGeAlD
Erlotinib—ABL1—digestive system—stomach cancer	0.000213	0.00591	CbGeAlD
Erlotinib—ORM1—bone marrow—stomach cancer	0.000207	0.00573	CbGeAlD
Erlotinib—MAP2K5—liver—stomach cancer	0.000206	0.00571	CbGeAlD
Erlotinib—SLK—lymph node—stomach cancer	0.000203	0.00563	CbGeAlD
Erlotinib—CYP2C8—hematopoietic system—stomach cancer	0.000199	0.00551	CbGeAlD
Erlotinib—ABL1—bone marrow—stomach cancer	0.000197	0.00545	CbGeAlD
Erlotinib—CYP1A2—hematopoietic system—stomach cancer	0.000186	0.00516	CbGeAlD
Erlotinib—ORM1—endocrine gland—stomach cancer	0.000186	0.00514	CbGeAlD
Erlotinib—CYP1A1—hematopoietic system—stomach cancer	0.000184	0.00509	CbGeAlD
Erlotinib—CYP1B1—lymphoid tissue—stomach cancer	0.000183	0.00507	CbGeAlD
Erlotinib—CYP1B1—digestive system—stomach cancer	0.000181	0.005	CbGeAlD
Erlotinib—CYP3A5—hematopoietic system—stomach cancer	0.00018	0.00497	CbGeAlD
Erlotinib—ABCB1—blood vessel—stomach cancer	0.000179	0.00496	CbGeAlD
Erlotinib—SLCO2B1—endocrine gland—stomach cancer	0.000178	0.00492	CbGeAlD
Erlotinib—STK10—lymph node—stomach cancer	0.000177	0.0049	CbGeAlD
Erlotinib—ABL1—endocrine gland—stomach cancer	0.000176	0.00488	CbGeAlD
Erlotinib—CYP1A1—epithelium—stomach cancer	0.000168	0.00465	CbGeAlD
Erlotinib—ORM1—liver—stomach cancer	0.000167	0.00463	CbGeAlD
Erlotinib—ABL1—Idarubicin—Epirubicin—stomach cancer	0.000164	0.0997	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Epirubicin—stomach cancer	0.000164	0.0997	CbGdCrCtD
Erlotinib—ABL1—Doxorubicin—Epirubicin—stomach cancer	0.000164	0.0997	CbGdCrCtD
Erlotinib—SLCO2B1—liver—stomach cancer	0.00016	0.00444	CbGeAlD
Erlotinib—ABL1—liver—stomach cancer	0.000159	0.0044	CbGeAlD
Erlotinib—MAP2K5—lymph node—stomach cancer	0.000158	0.00437	CbGeAlD
Erlotinib—ABL1—Epirubicin—Doxorubicin—stomach cancer	0.000152	0.0922	CbGdCrCtD
Erlotinib—ABL1—Idarubicin—Doxorubicin—stomach cancer	0.000152	0.0922	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Doxorubicin—stomach cancer	0.000152	0.0922	CbGdCrCtD
Erlotinib—CYP1B1—endocrine gland—stomach cancer	0.000149	0.00413	CbGeAlD
Erlotinib—ALB—liver—stomach cancer	0.000147	0.00406	CbGeAlD
Erlotinib—CYP3A5—pancreas—stomach cancer	0.000146	0.00405	CbGeAlD
Erlotinib—CYP3A4—hematopoietic system—stomach cancer	0.000135	0.00373	CbGeAlD
Erlotinib—CYP1B1—liver—stomach cancer	0.000135	0.00373	CbGeAlD
Erlotinib—CYP2D6—hematopoietic system—stomach cancer	0.000133	0.00367	CbGeAlD
Erlotinib—CYP1A2—digestive system—stomach cancer	0.000129	0.00359	CbGeAlD
Erlotinib—ORM1—lymph node—stomach cancer	0.000128	0.00355	CbGeAlD
Erlotinib—CYP1A1—digestive system—stomach cancer	0.000128	0.00354	CbGeAlD
Erlotinib—CYP3A5—digestive system—stomach cancer	0.000125	0.00346	CbGeAlD
Erlotinib—ABCG2—bone marrow—stomach cancer	0.000124	0.00343	CbGeAlD
Erlotinib—SLCO2B1—lymph node—stomach cancer	0.000123	0.0034	CbGeAlD
Erlotinib—ABL1—lymph node—stomach cancer	0.000122	0.00338	CbGeAlD
Erlotinib—CYP2C8—endocrine gland—stomach cancer	0.000114	0.00317	CbGeAlD
Erlotinib—ALB—lymph node—stomach cancer	0.000112	0.00311	CbGeAlD
Erlotinib—CYP1A2—endocrine gland—stomach cancer	0.000107	0.00296	CbGeAlD
Erlotinib—CYP1A1—endocrine gland—stomach cancer	0.000106	0.00292	CbGeAlD
Erlotinib—CYP1B1—lymph node—stomach cancer	0.000103	0.00286	CbGeAlD
Erlotinib—CYP3A5—endocrine gland—stomach cancer	0.000103	0.00286	CbGeAlD
Erlotinib—CYP2C8—liver—stomach cancer	0.000103	0.00285	CbGeAlD
Erlotinib—ABCG2—liver—stomach cancer	0.0001	0.00278	CbGeAlD
Erlotinib—CYP1A2—liver—stomach cancer	9.65e-05	0.00267	CbGeAlD
Erlotinib—ABCB1—hematopoietic system—stomach cancer	9.54e-05	0.00264	CbGeAlD
Erlotinib—CYP1A1—liver—stomach cancer	9.51e-05	0.00264	CbGeAlD
Erlotinib—CYP3A4—digestive system—stomach cancer	9.37e-05	0.0026	CbGeAlD
Erlotinib—CYP3A5—liver—stomach cancer	9.3e-05	0.00258	CbGeAlD
Erlotinib—CYP2D6—digestive system—stomach cancer	9.22e-05	0.00255	CbGeAlD
Erlotinib—ABCB1—epithelium—stomach cancer	8.72e-05	0.00242	CbGeAlD
Erlotinib—Vandetanib—ALB—stomach cancer	8.23e-05	0.0324	CrCbGaD
Erlotinib—Gefitinib—ALB—stomach cancer	7.82e-05	0.0308	CrCbGaD
Erlotinib—ABCB1—pancreas—stomach cancer	7.77e-05	0.00215	CbGeAlD
Erlotinib—CYP3A4—endocrine gland—stomach cancer	7.74e-05	0.00214	CbGeAlD
Erlotinib—ABCG2—lymph node—stomach cancer	7.68e-05	0.00213	CbGeAlD
Erlotinib—CYP2D6—endocrine gland—stomach cancer	7.62e-05	0.00211	CbGeAlD
Erlotinib—CYP1A1—lymph node—stomach cancer	7.29e-05	0.00202	CbGeAlD
Erlotinib—CYP3A4—liver—stomach cancer	6.98e-05	0.00193	CbGeAlD
Erlotinib—CYP2D6—liver—stomach cancer	6.87e-05	0.0019	CbGeAlD
Erlotinib—ABCB1—lymphoid tissue—stomach cancer	6.72e-05	0.00186	CbGeAlD
Erlotinib—ABCB1—digestive system—stomach cancer	6.63e-05	0.00184	CbGeAlD
Erlotinib—ABCB1—bone marrow—stomach cancer	6.11e-05	0.00169	CbGeAlD
Erlotinib—ABCB1—endocrine gland—stomach cancer	5.48e-05	0.00152	CbGeAlD
Erlotinib—ABCB1—liver—stomach cancer	4.94e-05	0.00137	CbGeAlD
Erlotinib—Chest pain—Docetaxel—stomach cancer	4.88e-05	0.000565	CcSEcCtD
Erlotinib—Arthralgia—Docetaxel—stomach cancer	4.88e-05	0.000565	CcSEcCtD
Erlotinib—Loss of consciousness—Capecitabine—stomach cancer	4.88e-05	0.000565	CcSEcCtD
Erlotinib—Renal failure—Epirubicin—stomach cancer	4.86e-05	0.000563	CcSEcCtD
Erlotinib—Asthenia—Irinotecan—stomach cancer	4.86e-05	0.000562	CcSEcCtD
Erlotinib—Neuropathy peripheral—Epirubicin—stomach cancer	4.85e-05	0.000562	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—stomach cancer	4.85e-05	0.000561	CcSEcCtD
Erlotinib—Cough—Capecitabine—stomach cancer	4.84e-05	0.000561	CcSEcCtD
Erlotinib—Stomatitis—Epirubicin—stomach cancer	4.82e-05	0.000558	CcSEcCtD
Erlotinib—Conjunctivitis—Epirubicin—stomach cancer	4.81e-05	0.000557	CcSEcCtD
Erlotinib—Neutropenia—Doxorubicin—stomach cancer	4.8e-05	0.000556	CcSEcCtD
Erlotinib—Haemoglobin—Methotrexate—stomach cancer	4.77e-05	0.000552	CcSEcCtD
Erlotinib—Haemorrhage—Methotrexate—stomach cancer	4.75e-05	0.00055	CcSEcCtD
Erlotinib—Hepatitis—Methotrexate—stomach cancer	4.75e-05	0.00055	CcSEcCtD
Erlotinib—Arthralgia—Capecitabine—stomach cancer	4.73e-05	0.000547	CcSEcCtD
Erlotinib—Chest pain—Capecitabine—stomach cancer	4.73e-05	0.000547	CcSEcCtD
Erlotinib—Myalgia—Capecitabine—stomach cancer	4.73e-05	0.000547	CcSEcCtD
Erlotinib—Anxiety—Capecitabine—stomach cancer	4.71e-05	0.000545	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—stomach cancer	4.69e-05	0.000543	CcSEcCtD
Erlotinib—Urinary tract disorder—Methotrexate—stomach cancer	4.69e-05	0.000543	CcSEcCtD
Erlotinib—Hepatobiliary disease—Epirubicin—stomach cancer	4.68e-05	0.000542	CcSEcCtD
Erlotinib—Oedema—Docetaxel—stomach cancer	4.68e-05	0.000542	CcSEcCtD
Erlotinib—Epistaxis—Epirubicin—stomach cancer	4.67e-05	0.00054	CcSEcCtD
Erlotinib—Urethral disorder—Methotrexate—stomach cancer	4.65e-05	0.000539	CcSEcCtD
Erlotinib—Infection—Docetaxel—stomach cancer	4.65e-05	0.000538	CcSEcCtD
Erlotinib—Weight decreased—Doxorubicin—stomach cancer	4.65e-05	0.000538	CcSEcCtD
Erlotinib—Diarrhoea—Irinotecan—stomach cancer	4.63e-05	0.000536	CcSEcCtD
Erlotinib—Pneumonia—Doxorubicin—stomach cancer	4.61e-05	0.000533	CcSEcCtD
Erlotinib—Shock—Docetaxel—stomach cancer	4.6e-05	0.000533	CcSEcCtD
Erlotinib—Nervous system disorder—Docetaxel—stomach cancer	4.59e-05	0.000531	CcSEcCtD
Erlotinib—Pruritus—Fluorouracil—stomach cancer	4.59e-05	0.000531	CcSEcCtD
Erlotinib—Thrombocytopenia—Docetaxel—stomach cancer	4.58e-05	0.00053	CcSEcCtD
Erlotinib—Infestation NOS—Doxorubicin—stomach cancer	4.58e-05	0.00053	CcSEcCtD
Erlotinib—Infestation—Doxorubicin—stomach cancer	4.58e-05	0.00053	CcSEcCtD
Erlotinib—Skin disorder—Docetaxel—stomach cancer	4.55e-05	0.000526	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Doxorubicin—stomach cancer	4.54e-05	0.000526	CcSEcCtD
Erlotinib—Oedema—Capecitabine—stomach cancer	4.53e-05	0.000525	CcSEcCtD
Erlotinib—Renal failure—Doxorubicin—stomach cancer	4.5e-05	0.000521	CcSEcCtD
Erlotinib—Infection—Capecitabine—stomach cancer	4.5e-05	0.000521	CcSEcCtD
Erlotinib—Erythema multiforme—Methotrexate—stomach cancer	4.49e-05	0.00052	CcSEcCtD
Erlotinib—Neuropathy peripheral—Doxorubicin—stomach cancer	4.49e-05	0.00052	CcSEcCtD
Erlotinib—Dizziness—Irinotecan—stomach cancer	4.48e-05	0.000518	CcSEcCtD
Erlotinib—Haemoglobin—Epirubicin—stomach cancer	4.46e-05	0.000517	CcSEcCtD
Erlotinib—Stomatitis—Doxorubicin—stomach cancer	4.46e-05	0.000517	CcSEcCtD
Erlotinib—Anorexia—Docetaxel—stomach cancer	4.46e-05	0.000516	CcSEcCtD
Erlotinib—Shock—Capecitabine—stomach cancer	4.46e-05	0.000516	CcSEcCtD
Erlotinib—Conjunctivitis—Doxorubicin—stomach cancer	4.45e-05	0.000515	CcSEcCtD
Erlotinib—Nervous system disorder—Capecitabine—stomach cancer	4.44e-05	0.000514	CcSEcCtD
Erlotinib—Haemorrhage—Epirubicin—stomach cancer	4.44e-05	0.000514	CcSEcCtD
Erlotinib—Hepatitis—Epirubicin—stomach cancer	4.44e-05	0.000514	CcSEcCtD
Erlotinib—Eye disorder—Methotrexate—stomach cancer	4.44e-05	0.000514	CcSEcCtD
Erlotinib—Diarrhoea—Fluorouracil—stomach cancer	4.44e-05	0.000514	CcSEcCtD
Erlotinib—Thrombocytopenia—Capecitabine—stomach cancer	4.44e-05	0.000514	CcSEcCtD
Erlotinib—Skin disorder—Capecitabine—stomach cancer	4.4e-05	0.000509	CcSEcCtD
Erlotinib—Urinary tract disorder—Epirubicin—stomach cancer	4.39e-05	0.000508	CcSEcCtD
Erlotinib—Connective tissue disorder—Epirubicin—stomach cancer	4.37e-05	0.000505	CcSEcCtD
Erlotinib—Urethral disorder—Epirubicin—stomach cancer	4.35e-05	0.000504	CcSEcCtD
Erlotinib—Hepatobiliary disease—Doxorubicin—stomach cancer	4.33e-05	0.000501	CcSEcCtD
Erlotinib—Epistaxis—Doxorubicin—stomach cancer	4.32e-05	0.0005	CcSEcCtD
Erlotinib—Anorexia—Capecitabine—stomach cancer	4.32e-05	0.0005	CcSEcCtD
Erlotinib—Vomiting—Irinotecan—stomach cancer	4.3e-05	0.000498	CcSEcCtD
Erlotinib—Dizziness—Fluorouracil—stomach cancer	4.29e-05	0.000496	CcSEcCtD
Erlotinib—Mediastinal disorder—Methotrexate—stomach cancer	4.28e-05	0.000495	CcSEcCtD
Erlotinib—Rash—Irinotecan—stomach cancer	4.27e-05	0.000494	CcSEcCtD
Erlotinib—Dermatitis—Irinotecan—stomach cancer	4.26e-05	0.000494	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Docetaxel—stomach cancer	4.26e-05	0.000494	CcSEcCtD
Erlotinib—Chills—Methotrexate—stomach cancer	4.26e-05	0.000493	CcSEcCtD
Erlotinib—Headache—Irinotecan—stomach cancer	4.24e-05	0.000491	CcSEcCtD
Erlotinib—Insomnia—Docetaxel—stomach cancer	4.23e-05	0.00049	CcSEcCtD
Erlotinib—Erythema multiforme—Epirubicin—stomach cancer	4.2e-05	0.000486	CcSEcCtD
Erlotinib—Alopecia—Methotrexate—stomach cancer	4.19e-05	0.000486	CcSEcCtD
Erlotinib—Dyspnoea—Docetaxel—stomach cancer	4.17e-05	0.000483	CcSEcCtD
Erlotinib—Mental disorder—Methotrexate—stomach cancer	4.16e-05	0.000482	CcSEcCtD
Erlotinib—Eye disorder—Epirubicin—stomach cancer	4.15e-05	0.000481	CcSEcCtD
Erlotinib—Erythema—Methotrexate—stomach cancer	4.13e-05	0.000478	CcSEcCtD
Erlotinib—Malnutrition—Methotrexate—stomach cancer	4.13e-05	0.000478	CcSEcCtD
Erlotinib—Haemoglobin—Doxorubicin—stomach cancer	4.13e-05	0.000478	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Capecitabine—stomach cancer	4.13e-05	0.000478	CcSEcCtD
Erlotinib—Vomiting—Fluorouracil—stomach cancer	4.12e-05	0.000477	CcSEcCtD
Erlotinib—Dyspepsia—Docetaxel—stomach cancer	4.12e-05	0.000477	CcSEcCtD
Erlotinib—Haemorrhage—Doxorubicin—stomach cancer	4.11e-05	0.000476	CcSEcCtD
Erlotinib—Hepatitis—Doxorubicin—stomach cancer	4.11e-05	0.000476	CcSEcCtD
Erlotinib—Insomnia—Capecitabine—stomach cancer	4.1e-05	0.000474	CcSEcCtD
Erlotinib—Rash—Fluorouracil—stomach cancer	4.09e-05	0.000473	CcSEcCtD
Erlotinib—Dermatitis—Fluorouracil—stomach cancer	4.08e-05	0.000473	CcSEcCtD
Erlotinib—Decreased appetite—Docetaxel—stomach cancer	4.07e-05	0.000471	CcSEcCtD
Erlotinib—Headache—Fluorouracil—stomach cancer	4.06e-05	0.00047	CcSEcCtD
Erlotinib—Urinary tract disorder—Doxorubicin—stomach cancer	4.06e-05	0.00047	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Docetaxel—stomach cancer	4.04e-05	0.000468	CcSEcCtD
Erlotinib—Connective tissue disorder—Doxorubicin—stomach cancer	4.04e-05	0.000468	CcSEcCtD
Erlotinib—Dyspnoea—Capecitabine—stomach cancer	4.04e-05	0.000468	CcSEcCtD
Erlotinib—Fatigue—Docetaxel—stomach cancer	4.03e-05	0.000467	CcSEcCtD
Erlotinib—Urethral disorder—Doxorubicin—stomach cancer	4.03e-05	0.000467	CcSEcCtD
Erlotinib—Nausea—Irinotecan—stomach cancer	4.02e-05	0.000466	CcSEcCtD
Erlotinib—Mediastinal disorder—Epirubicin—stomach cancer	4e-05	0.000464	CcSEcCtD
Erlotinib—Pain—Docetaxel—stomach cancer	4e-05	0.000463	CcSEcCtD
Erlotinib—Constipation—Docetaxel—stomach cancer	4e-05	0.000463	CcSEcCtD
Erlotinib—Back pain—Methotrexate—stomach cancer	4e-05	0.000463	CcSEcCtD
Erlotinib—Dyspepsia—Capecitabine—stomach cancer	3.99e-05	0.000462	CcSEcCtD
Erlotinib—Chills—Epirubicin—stomach cancer	3.99e-05	0.000462	CcSEcCtD
Erlotinib—Arrhythmia—Epirubicin—stomach cancer	3.97e-05	0.000459	CcSEcCtD
Erlotinib—Decreased appetite—Capecitabine—stomach cancer	3.94e-05	0.000456	CcSEcCtD
Erlotinib—Alopecia—Epirubicin—stomach cancer	3.93e-05	0.000455	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Capecitabine—stomach cancer	3.91e-05	0.000453	CcSEcCtD
Erlotinib—Fatigue—Capecitabine—stomach cancer	3.91e-05	0.000452	CcSEcCtD
Erlotinib—Mental disorder—Epirubicin—stomach cancer	3.89e-05	0.000451	CcSEcCtD
Erlotinib—Erythema multiforme—Doxorubicin—stomach cancer	3.89e-05	0.00045	CcSEcCtD
Erlotinib—Pain—Capecitabine—stomach cancer	3.87e-05	0.000449	CcSEcCtD
Erlotinib—Constipation—Capecitabine—stomach cancer	3.87e-05	0.000449	CcSEcCtD
Erlotinib—Erythema—Epirubicin—stomach cancer	3.87e-05	0.000448	CcSEcCtD
Erlotinib—Malnutrition—Epirubicin—stomach cancer	3.87e-05	0.000448	CcSEcCtD
Erlotinib—Nausea—Fluorouracil—stomach cancer	3.85e-05	0.000446	CcSEcCtD
Erlotinib—Eye disorder—Doxorubicin—stomach cancer	3.84e-05	0.000445	CcSEcCtD
Erlotinib—Gastrointestinal pain—Docetaxel—stomach cancer	3.83e-05	0.000443	CcSEcCtD
Erlotinib—Flatulence—Epirubicin—stomach cancer	3.81e-05	0.000441	CcSEcCtD
Erlotinib—ABCB1—lymph node—stomach cancer	3.79e-05	0.00105	CbGeAlD
Erlotinib—Back pain—Epirubicin—stomach cancer	3.74e-05	0.000433	CcSEcCtD
Erlotinib—Gastrointestinal pain—Capecitabine—stomach cancer	3.7e-05	0.000429	CcSEcCtD
Erlotinib—Mediastinal disorder—Doxorubicin—stomach cancer	3.7e-05	0.000429	CcSEcCtD
Erlotinib—Body temperature increased—Docetaxel—stomach cancer	3.7e-05	0.000428	CcSEcCtD
Erlotinib—Abdominal pain—Docetaxel—stomach cancer	3.7e-05	0.000428	CcSEcCtD
Erlotinib—Chills—Doxorubicin—stomach cancer	3.69e-05	0.000427	CcSEcCtD
Erlotinib—Arrhythmia—Doxorubicin—stomach cancer	3.67e-05	0.000425	CcSEcCtD
Erlotinib—Alopecia—Doxorubicin—stomach cancer	3.63e-05	0.000421	CcSEcCtD
Erlotinib—Cough—Methotrexate—stomach cancer	3.61e-05	0.000418	CcSEcCtD
Erlotinib—Mental disorder—Doxorubicin—stomach cancer	3.6e-05	0.000417	CcSEcCtD
Erlotinib—Body temperature increased—Capecitabine—stomach cancer	3.58e-05	0.000415	CcSEcCtD
Erlotinib—Abdominal pain—Capecitabine—stomach cancer	3.58e-05	0.000415	CcSEcCtD
Erlotinib—Erythema—Doxorubicin—stomach cancer	3.58e-05	0.000414	CcSEcCtD
Erlotinib—Malnutrition—Doxorubicin—stomach cancer	3.58e-05	0.000414	CcSEcCtD
Erlotinib—Flatulence—Doxorubicin—stomach cancer	3.53e-05	0.000408	CcSEcCtD
Erlotinib—Myalgia—Methotrexate—stomach cancer	3.52e-05	0.000407	CcSEcCtD
Erlotinib—Chest pain—Methotrexate—stomach cancer	3.52e-05	0.000407	CcSEcCtD
Erlotinib—Arthralgia—Methotrexate—stomach cancer	3.52e-05	0.000407	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	3.49e-05	0.000405	CcSEcCtD
Erlotinib—Syncope—Epirubicin—stomach cancer	3.47e-05	0.000402	CcSEcCtD
Erlotinib—Back pain—Doxorubicin—stomach cancer	3.46e-05	0.000401	CcSEcCtD
Erlotinib—Loss of consciousness—Epirubicin—stomach cancer	3.4e-05	0.000394	CcSEcCtD
Erlotinib—Cough—Epirubicin—stomach cancer	3.37e-05	0.000391	CcSEcCtD
Erlotinib—Asthenia—Docetaxel—stomach cancer	3.36e-05	0.000389	CcSEcCtD
Erlotinib—Infection—Methotrexate—stomach cancer	3.35e-05	0.000388	CcSEcCtD
Erlotinib—Pruritus—Docetaxel—stomach cancer	3.31e-05	0.000383	CcSEcCtD
Erlotinib—Nervous system disorder—Methotrexate—stomach cancer	3.31e-05	0.000383	CcSEcCtD
Erlotinib—Thrombocytopenia—Methotrexate—stomach cancer	3.3e-05	0.000382	CcSEcCtD
Erlotinib—Myalgia—Epirubicin—stomach cancer	3.29e-05	0.000381	CcSEcCtD
Erlotinib—Chest pain—Epirubicin—stomach cancer	3.29e-05	0.000381	CcSEcCtD
Erlotinib—Arthralgia—Epirubicin—stomach cancer	3.29e-05	0.000381	CcSEcCtD
Erlotinib—Anxiety—Epirubicin—stomach cancer	3.28e-05	0.00038	CcSEcCtD
Erlotinib—Skin disorder—Methotrexate—stomach cancer	3.28e-05	0.000379	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	3.27e-05	0.000379	CcSEcCtD
Erlotinib—Asthenia—Capecitabine—stomach cancer	3.25e-05	0.000376	CcSEcCtD
Erlotinib—Anorexia—Methotrexate—stomach cancer	3.21e-05	0.000372	CcSEcCtD
Erlotinib—Syncope—Doxorubicin—stomach cancer	3.21e-05	0.000372	CcSEcCtD
Erlotinib—Pruritus—Capecitabine—stomach cancer	3.21e-05	0.000371	CcSEcCtD
Erlotinib—Diarrhoea—Docetaxel—stomach cancer	3.2e-05	0.000371	CcSEcCtD
Erlotinib—Oedema—Epirubicin—stomach cancer	3.16e-05	0.000365	CcSEcCtD
Erlotinib—Loss of consciousness—Doxorubicin—stomach cancer	3.14e-05	0.000364	CcSEcCtD
Erlotinib—Infection—Epirubicin—stomach cancer	3.14e-05	0.000363	CcSEcCtD
Erlotinib—Cough—Doxorubicin—stomach cancer	3.12e-05	0.000362	CcSEcCtD
Erlotinib—Shock—Epirubicin—stomach cancer	3.11e-05	0.00036	CcSEcCtD
Erlotinib—Diarrhoea—Capecitabine—stomach cancer	3.1e-05	0.000359	CcSEcCtD
Erlotinib—Nervous system disorder—Epirubicin—stomach cancer	3.1e-05	0.000358	CcSEcCtD
Erlotinib—Dizziness—Docetaxel—stomach cancer	3.09e-05	0.000358	CcSEcCtD
Erlotinib—Thrombocytopenia—Epirubicin—stomach cancer	3.09e-05	0.000358	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Methotrexate—stomach cancer	3.07e-05	0.000356	CcSEcCtD
Erlotinib—Skin disorder—Epirubicin—stomach cancer	3.07e-05	0.000355	CcSEcCtD
Erlotinib—Insomnia—Methotrexate—stomach cancer	3.05e-05	0.000353	CcSEcCtD
Erlotinib—Chest pain—Doxorubicin—stomach cancer	3.05e-05	0.000353	CcSEcCtD
Erlotinib—Myalgia—Doxorubicin—stomach cancer	3.05e-05	0.000353	CcSEcCtD
Erlotinib—Arthralgia—Doxorubicin—stomach cancer	3.05e-05	0.000353	CcSEcCtD
Erlotinib—Anxiety—Doxorubicin—stomach cancer	3.04e-05	0.000351	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	3.03e-05	0.00035	CcSEcCtD
Erlotinib—Anorexia—Epirubicin—stomach cancer	3.01e-05	0.000348	CcSEcCtD
Erlotinib—Dyspnoea—Methotrexate—stomach cancer	3.01e-05	0.000348	CcSEcCtD
Erlotinib—Dizziness—Capecitabine—stomach cancer	3e-05	0.000347	CcSEcCtD
Erlotinib—Vomiting—Docetaxel—stomach cancer	2.98e-05	0.000344	CcSEcCtD
Erlotinib—Dyspepsia—Methotrexate—stomach cancer	2.97e-05	0.000344	CcSEcCtD
Erlotinib—Rash—Docetaxel—stomach cancer	2.95e-05	0.000342	CcSEcCtD
Erlotinib—Dermatitis—Docetaxel—stomach cancer	2.95e-05	0.000341	CcSEcCtD
Erlotinib—Decreased appetite—Methotrexate—stomach cancer	2.93e-05	0.000339	CcSEcCtD
Erlotinib—Headache—Docetaxel—stomach cancer	2.93e-05	0.000339	CcSEcCtD
Erlotinib—Oedema—Doxorubicin—stomach cancer	2.92e-05	0.000338	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Methotrexate—stomach cancer	2.91e-05	0.000337	CcSEcCtD
Erlotinib—Fatigue—Methotrexate—stomach cancer	2.91e-05	0.000337	CcSEcCtD
Erlotinib—Infection—Doxorubicin—stomach cancer	2.9e-05	0.000336	CcSEcCtD
Erlotinib—Pain—Methotrexate—stomach cancer	2.88e-05	0.000334	CcSEcCtD
Erlotinib—Vomiting—Capecitabine—stomach cancer	2.88e-05	0.000334	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Epirubicin—stomach cancer	2.88e-05	0.000333	CcSEcCtD
Erlotinib—Shock—Doxorubicin—stomach cancer	2.87e-05	0.000333	CcSEcCtD
Erlotinib—Nervous system disorder—Doxorubicin—stomach cancer	2.86e-05	0.000332	CcSEcCtD
Erlotinib—Thrombocytopenia—Doxorubicin—stomach cancer	2.86e-05	0.000331	CcSEcCtD
Erlotinib—Rash—Capecitabine—stomach cancer	2.86e-05	0.000331	CcSEcCtD
Erlotinib—Insomnia—Epirubicin—stomach cancer	2.85e-05	0.000331	CcSEcCtD
Erlotinib—Dermatitis—Capecitabine—stomach cancer	2.85e-05	0.00033	CcSEcCtD
Erlotinib—Headache—Capecitabine—stomach cancer	2.84e-05	0.000329	CcSEcCtD
Erlotinib—Skin disorder—Doxorubicin—stomach cancer	2.84e-05	0.000328	CcSEcCtD
Erlotinib—Dyspnoea—Epirubicin—stomach cancer	2.81e-05	0.000326	CcSEcCtD
Erlotinib—Anorexia—Doxorubicin—stomach cancer	2.78e-05	0.000322	CcSEcCtD
Erlotinib—Nausea—Docetaxel—stomach cancer	2.78e-05	0.000322	CcSEcCtD
Erlotinib—Dyspepsia—Epirubicin—stomach cancer	2.78e-05	0.000322	CcSEcCtD
Erlotinib—Gastrointestinal pain—Methotrexate—stomach cancer	2.76e-05	0.000319	CcSEcCtD
Erlotinib—Decreased appetite—Epirubicin—stomach cancer	2.74e-05	0.000318	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Epirubicin—stomach cancer	2.72e-05	0.000315	CcSEcCtD
Erlotinib—Fatigue—Epirubicin—stomach cancer	2.72e-05	0.000315	CcSEcCtD
Erlotinib—Pain—Epirubicin—stomach cancer	2.7e-05	0.000312	CcSEcCtD
Erlotinib—Constipation—Epirubicin—stomach cancer	2.7e-05	0.000312	CcSEcCtD
Erlotinib—Nausea—Capecitabine—stomach cancer	2.69e-05	0.000312	CcSEcCtD
Erlotinib—Body temperature increased—Methotrexate—stomach cancer	2.67e-05	0.000309	CcSEcCtD
Erlotinib—Abdominal pain—Methotrexate—stomach cancer	2.67e-05	0.000309	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Doxorubicin—stomach cancer	2.66e-05	0.000308	CcSEcCtD
Erlotinib—Insomnia—Doxorubicin—stomach cancer	2.64e-05	0.000306	CcSEcCtD
Erlotinib—Dyspnoea—Doxorubicin—stomach cancer	2.6e-05	0.000301	CcSEcCtD
Erlotinib—Gastrointestinal pain—Epirubicin—stomach cancer	2.58e-05	0.000299	CcSEcCtD
Erlotinib—Dyspepsia—Doxorubicin—stomach cancer	2.57e-05	0.000298	CcSEcCtD
Erlotinib—Decreased appetite—Doxorubicin—stomach cancer	2.54e-05	0.000294	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Doxorubicin—stomach cancer	2.52e-05	0.000292	CcSEcCtD
Erlotinib—Fatigue—Doxorubicin—stomach cancer	2.52e-05	0.000292	CcSEcCtD
Erlotinib—Constipation—Doxorubicin—stomach cancer	2.5e-05	0.000289	CcSEcCtD
Erlotinib—Pain—Doxorubicin—stomach cancer	2.5e-05	0.000289	CcSEcCtD
Erlotinib—Abdominal pain—Epirubicin—stomach cancer	2.49e-05	0.000289	CcSEcCtD
Erlotinib—Body temperature increased—Epirubicin—stomach cancer	2.49e-05	0.000289	CcSEcCtD
Erlotinib—Asthenia—Methotrexate—stomach cancer	2.42e-05	0.00028	CcSEcCtD
Erlotinib—Gastrointestinal pain—Doxorubicin—stomach cancer	2.39e-05	0.000276	CcSEcCtD
Erlotinib—Pruritus—Methotrexate—stomach cancer	2.39e-05	0.000276	CcSEcCtD
Erlotinib—Body temperature increased—Doxorubicin—stomach cancer	2.31e-05	0.000267	CcSEcCtD
Erlotinib—Abdominal pain—Doxorubicin—stomach cancer	2.31e-05	0.000267	CcSEcCtD
Erlotinib—Diarrhoea—Methotrexate—stomach cancer	2.31e-05	0.000267	CcSEcCtD
Erlotinib—Asthenia—Epirubicin—stomach cancer	2.26e-05	0.000262	CcSEcCtD
Erlotinib—Pruritus—Epirubicin—stomach cancer	2.23e-05	0.000259	CcSEcCtD
Erlotinib—Dizziness—Methotrexate—stomach cancer	2.23e-05	0.000258	CcSEcCtD
Erlotinib—Diarrhoea—Epirubicin—stomach cancer	2.16e-05	0.00025	CcSEcCtD
Erlotinib—Vomiting—Methotrexate—stomach cancer	2.14e-05	0.000248	CcSEcCtD
Erlotinib—Rash—Methotrexate—stomach cancer	2.13e-05	0.000246	CcSEcCtD
Erlotinib—Dermatitis—Methotrexate—stomach cancer	2.12e-05	0.000246	CcSEcCtD
Erlotinib—Headache—Methotrexate—stomach cancer	2.11e-05	0.000245	CcSEcCtD
Erlotinib—Asthenia—Doxorubicin—stomach cancer	2.1e-05	0.000243	CcSEcCtD
Erlotinib—Dizziness—Epirubicin—stomach cancer	2.09e-05	0.000242	CcSEcCtD
Erlotinib—Pruritus—Doxorubicin—stomach cancer	2.07e-05	0.000239	CcSEcCtD
Erlotinib—Vomiting—Epirubicin—stomach cancer	2.01e-05	0.000232	CcSEcCtD
Erlotinib—Nausea—Methotrexate—stomach cancer	2e-05	0.000232	CcSEcCtD
Erlotinib—Diarrhoea—Doxorubicin—stomach cancer	2e-05	0.000231	CcSEcCtD
Erlotinib—Rash—Epirubicin—stomach cancer	1.99e-05	0.00023	CcSEcCtD
Erlotinib—Dermatitis—Epirubicin—stomach cancer	1.99e-05	0.00023	CcSEcCtD
Erlotinib—Headache—Epirubicin—stomach cancer	1.98e-05	0.000229	CcSEcCtD
Erlotinib—Dizziness—Doxorubicin—stomach cancer	1.93e-05	0.000224	CcSEcCtD
Erlotinib—Nausea—Epirubicin—stomach cancer	1.87e-05	0.000217	CcSEcCtD
Erlotinib—Vomiting—Doxorubicin—stomach cancer	1.86e-05	0.000215	CcSEcCtD
Erlotinib—Rash—Doxorubicin—stomach cancer	1.84e-05	0.000213	CcSEcCtD
Erlotinib—Dermatitis—Doxorubicin—stomach cancer	1.84e-05	0.000213	CcSEcCtD
Erlotinib—Headache—Doxorubicin—stomach cancer	1.83e-05	0.000212	CcSEcCtD
Erlotinib—Nausea—Doxorubicin—stomach cancer	1.73e-05	0.000201	CcSEcCtD
Erlotinib—CYP1B1—Metabolism—PPARG—stomach cancer	1.59e-06	2.29e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	1.59e-06	2.29e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	1.58e-06	2.28e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MAPK8—stomach cancer	1.57e-06	2.27e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GSTP1—stomach cancer	1.57e-06	2.27e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ALOX5—stomach cancer	1.57e-06	2.27e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KRAS—stomach cancer	1.56e-06	2.25e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKR1C3—stomach cancer	1.55e-06	2.24e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—HMOX1—stomach cancer	1.55e-06	2.24e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—DPYD—stomach cancer	1.55e-06	2.23e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—HRAS—stomach cancer	1.54e-06	2.22e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ALB—stomach cancer	1.53e-06	2.21e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IRS2—stomach cancer	1.52e-06	2.19e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PPP2R1A—stomach cancer	1.52e-06	2.19e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ENO1—stomach cancer	1.51e-06	2.18e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TYMP—stomach cancer	1.51e-06	2.17e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—FADS1—stomach cancer	1.51e-06	2.17e-05	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—ALB—stomach cancer	1.5e-06	2.17e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VEGFA—stomach cancer	1.5e-06	2.16e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CDKN1B—stomach cancer	1.49e-06	2.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—ERBB2—stomach cancer	1.49e-06	2.15e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GSTP1—stomach cancer	1.49e-06	2.15e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—STAT3—stomach cancer	1.48e-06	2.14e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HRAS—stomach cancer	1.48e-06	2.14e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—IL6—stomach cancer	1.47e-06	2.13e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CAV1—stomach cancer	1.47e-06	2.13e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—APOA1—stomach cancer	1.47e-06	2.12e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL1B—stomach cancer	1.47e-06	2.12e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—HMOX1—stomach cancer	1.47e-06	2.12e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—NOS3—stomach cancer	1.47e-06	2.12e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—TYMS—stomach cancer	1.46e-06	2.11e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTGS2—stomach cancer	1.46e-06	2.1e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PPARG—stomach cancer	1.45e-06	2.09e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GSTM1—stomach cancer	1.45e-06	2.09e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—STAT3—stomach cancer	1.44e-06	2.08e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PIK3CA—stomach cancer	1.43e-06	2.07e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ALB—stomach cancer	1.43e-06	2.06e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CD44—stomach cancer	1.42e-06	2.05e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—JUN—stomach cancer	1.42e-06	2.05e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MAPK3—stomach cancer	1.42e-06	2.04e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SREBF2—stomach cancer	1.41e-06	2.03e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PRKCB—stomach cancer	1.4e-06	2.02e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—stomach cancer	1.4e-06	2.02e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6ST—stomach cancer	1.4e-06	2.02e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—RORA—stomach cancer	1.39e-06	2.01e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PPP2R1A—stomach cancer	1.39e-06	2.01e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—stomach cancer	1.39e-06	2e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—TYMS—stomach cancer	1.38e-06	1.99e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PPP2R1A—stomach cancer	1.38e-06	1.99e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CDKN1B—stomach cancer	1.38e-06	1.99e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CDKN1A—stomach cancer	1.38e-06	1.99e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MYC—stomach cancer	1.38e-06	1.99e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MAPK3—stomach cancer	1.38e-06	1.98e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTT1—stomach cancer	1.37e-06	1.97e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—NOS3—stomach cancer	1.37e-06	1.97e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GSTM1—stomach cancer	1.37e-06	1.97e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VEGFA—stomach cancer	1.36e-06	1.97e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTP1—stomach cancer	1.36e-06	1.97e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ERCC2—stomach cancer	1.36e-06	1.96e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTP1—stomach cancer	1.36e-06	1.96e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP2A6—stomach cancer	1.35e-06	1.95e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MAPK1—stomach cancer	1.35e-06	1.94e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EGFR—stomach cancer	1.35e-06	1.94e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MAPK8—stomach cancer	1.35e-06	1.94e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—HMOX1—stomach cancer	1.34e-06	1.94e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—APC—stomach cancer	1.34e-06	1.94e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CD44—stomach cancer	1.34e-06	1.94e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTGS2—stomach cancer	1.34e-06	1.94e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—HMOX1—stomach cancer	1.34e-06	1.93e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HRAS—stomach cancer	1.33e-06	1.91e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKR1C3—stomach cancer	1.32e-06	1.9e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MAPK1—stomach cancer	1.31e-06	1.89e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EGFR—stomach cancer	1.31e-06	1.89e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALDOB—stomach cancer	1.31e-06	1.88e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ALB—stomach cancer	1.3e-06	1.88e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—MAPK3—stomach cancer	1.29e-06	1.86e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—MAPK3—stomach cancer	1.29e-06	1.86e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ERCC2—stomach cancer	1.28e-06	1.85e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ENO1—stomach cancer	1.28e-06	1.85e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—MTHFR—stomach cancer	1.28e-06	1.84e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CDKN1A—stomach cancer	1.27e-06	1.84e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KRAS—stomach cancer	1.27e-06	1.84e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL6—stomach cancer	1.27e-06	1.83e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—TYMS—stomach cancer	1.27e-06	1.83e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—stomach cancer	1.26e-06	1.82e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—TYMS—stomach cancer	1.26e-06	1.82e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTM1—stomach cancer	1.25e-06	1.81e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTGS2—stomach cancer	1.25e-06	1.81e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6R—stomach cancer	1.25e-06	1.8e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTM1—stomach cancer	1.25e-06	1.8e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—NOS3—stomach cancer	1.24e-06	1.8e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KRAS—stomach cancer	1.24e-06	1.78e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—STAT3—stomach cancer	1.23e-06	1.77e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—MAPK1—stomach cancer	1.23e-06	1.77e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—MAPK1—stomach cancer	1.22e-06	1.77e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALOX5—stomach cancer	1.21e-06	1.75e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPP2R1A—stomach cancer	1.21e-06	1.75e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MTHFR—stomach cancer	1.21e-06	1.74e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—DPYD—stomach cancer	1.19e-06	1.72e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTP1—stomach cancer	1.19e-06	1.71e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CAV1—stomach cancer	1.18e-06	1.7e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ERCC2—stomach cancer	1.18e-06	1.7e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—APOA1—stomach cancer	1.18e-06	1.7e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MAPK3—stomach cancer	1.17e-06	1.7e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—HMOX1—stomach cancer	1.17e-06	1.69e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ERCC2—stomach cancer	1.17e-06	1.69e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PIK3CA—stomach cancer	1.17e-06	1.69e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SERPINE1—stomach cancer	1.17e-06	1.68e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—KRAS—stomach cancer	1.16e-06	1.67e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—KRAS—stomach cancer	1.16e-06	1.67e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPP2R1A—stomach cancer	1.14e-06	1.65e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—stomach cancer	1.14e-06	1.64e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CD44—stomach cancer	1.14e-06	1.64e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—STAT3—stomach cancer	1.14e-06	1.64e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PIK3CA—stomach cancer	1.14e-06	1.64e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—stomach cancer	1.13e-06	1.63e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—RHOA—stomach cancer	1.13e-06	1.63e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTP1—stomach cancer	1.12e-06	1.62e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MAPK1—stomach cancer	1.12e-06	1.61e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NOS3—stomach cancer	1.11e-06	1.61e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CAV1—stomach cancer	1.11e-06	1.61e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—APOA1—stomach cancer	1.11e-06	1.6e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MTHFR—stomach cancer	1.11e-06	1.6e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TYMS—stomach cancer	1.1e-06	1.59e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—HMOX1—stomach cancer	1.1e-06	1.59e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	1.1e-06	1.59e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MTHFR—stomach cancer	1.1e-06	1.59e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTM1—stomach cancer	1.09e-06	1.57e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MAPK3—stomach cancer	1.08e-06	1.57e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HRAS—stomach cancer	1.08e-06	1.56e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PIK3CA—stomach cancer	1.07e-06	1.54e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	1.06e-06	1.54e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PIK3CA—stomach cancer	1.06e-06	1.53e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KRAS—stomach cancer	1.06e-06	1.52e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTT1—stomach cancer	1.06e-06	1.52e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MYC—stomach cancer	1.06e-06	1.52e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HRAS—stomach cancer	1.05e-06	1.52e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP2A6—stomach cancer	1.04e-06	1.51e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ERBB2—stomach cancer	1.04e-06	1.5e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TYMS—stomach cancer	1.04e-06	1.5e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PPARG—stomach cancer	1.04e-06	1.5e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6—stomach cancer	1.04e-06	1.49e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MAPK1—stomach cancer	1.03e-06	1.49e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—stomach cancer	1.03e-06	1.49e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTM1—stomach cancer	1.03e-06	1.48e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ERCC2—stomach cancer	1.03e-06	1.48e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CAV1—stomach cancer	1.02e-06	1.47e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—APOA1—stomach cancer	1.02e-06	1.47e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CAV1—stomach cancer	1.02e-06	1.47e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKR1C3—stomach cancer	1.02e-06	1.46e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—APOA1—stomach cancer	1.01e-06	1.46e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6—stomach cancer	1.01e-06	1.45e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ENO1—stomach cancer	9.89e-07	1.43e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCL8—stomach cancer	9.89e-07	1.43e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HRAS—stomach cancer	9.86e-07	1.42e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HRAS—stomach cancer	9.82e-07	1.42e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PPARG—stomach cancer	9.79e-07	1.41e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	9.76e-07	1.41e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—KRAS—stomach cancer	9.75e-07	1.41e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	9.7e-07	1.4e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PIK3CA—stomach cancer	9.7e-07	1.4e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ERCC2—stomach cancer	9.67e-07	1.4e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPP2R1A—stomach cancer	9.67e-07	1.39e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDKN1B—stomach cancer	9.66e-07	1.39e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MTHFR—stomach cancer	9.65e-07	1.39e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTP1—stomach cancer	9.48e-07	1.37e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6—stomach cancer	9.4e-07	1.36e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HMOX1—stomach cancer	9.35e-07	1.35e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ALB—stomach cancer	9.32e-07	1.34e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCND1—stomach cancer	9.21e-07	1.33e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—JUN—stomach cancer	9.19e-07	1.33e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MTHFR—stomach cancer	9.09e-07	1.31e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PPARG—stomach cancer	8.98e-07	1.3e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HRAS—stomach cancer	8.98e-07	1.3e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PIK3CA—stomach cancer	8.96e-07	1.29e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MMP9—stomach cancer	8.94e-07	1.29e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PPARG—stomach cancer	8.93e-07	1.29e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NOS3—stomach cancer	8.92e-07	1.29e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDKN1A—stomach cancer	8.91e-07	1.29e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CAV1—stomach cancer	8.9e-07	1.28e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—APOA1—stomach cancer	8.88e-07	1.28e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TYMS—stomach cancer	8.82e-07	1.27e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ALB—stomach cancer	8.81e-07	1.27e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CD44—stomach cancer	8.77e-07	1.27e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTM1—stomach cancer	8.71e-07	1.26e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK8—stomach cancer	8.7e-07	1.25e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6—stomach cancer	8.59e-07	1.24e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—NOS3—stomach cancer	8.42e-07	1.22e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CAV1—stomach cancer	8.39e-07	1.21e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—APOA1—stomach cancer	8.37e-07	1.21e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—HRAS—stomach cancer	8.29e-07	1.2e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CA—stomach cancer	8.25e-07	1.19e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ERCC2—stomach cancer	8.19e-07	1.18e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—stomach cancer	8.16e-07	1.18e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ALB—stomach cancer	8.07e-07	1.16e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—stomach cancer	8.03e-07	1.16e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—STAT3—stomach cancer	7.95e-07	1.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6—stomach cancer	7.93e-07	1.14e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPARG—stomach cancer	7.82e-07	1.13e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NOS3—stomach cancer	7.72e-07	1.11e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—stomach cancer	7.7e-07	1.11e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MTHFR—stomach cancer	7.7e-07	1.11e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CA—stomach cancer	7.7e-07	1.11e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NOS3—stomach cancer	7.68e-07	1.11e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK3—stomach cancer	7.6e-07	1.1e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPP2R1A—stomach cancer	7.46e-07	1.08e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MYC—stomach cancer	7.39e-07	1.07e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPARG—stomach cancer	7.37e-07	1.06e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTP1—stomach cancer	7.32e-07	1.06e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK1—stomach cancer	7.23e-07	1.04e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HMOX1—stomach cancer	7.22e-07	1.04e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CAV1—stomach cancer	7.1e-07	1.02e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—APOA1—stomach cancer	7.09e-07	1.02e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—stomach cancer	7.06e-07	1.02e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ALB—stomach cancer	7.03e-07	1.01e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—stomach cancer	7.02e-07	1.01e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CA—stomach cancer	7e-07	1.01e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KRAS—stomach cancer	6.83e-07	9.85e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TYMS—stomach cancer	6.8e-07	9.82e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	6.79e-07	9.79e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NOS3—stomach cancer	6.73e-07	9.71e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTM1—stomach cancer	6.73e-07	9.7e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ALB—stomach cancer	6.63e-07	9.56e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NOS3—stomach cancer	6.34e-07	9.15e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ERCC2—stomach cancer	6.32e-07	9.12e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CA—stomach cancer	6.27e-07	9.05e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPARG—stomach cancer	6.25e-07	9.01e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—stomach cancer	6.15e-07	8.88e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—stomach cancer	6.07e-07	8.75e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MTHFR—stomach cancer	5.94e-07	8.58e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HRAS—stomach cancer	5.8e-07	8.37e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—stomach cancer	5.8e-07	8.37e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ALB—stomach cancer	5.62e-07	8.1e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6—stomach cancer	5.55e-07	8.01e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CAV1—stomach cancer	5.48e-07	7.91e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—APOA1—stomach cancer	5.47e-07	7.89e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NOS3—stomach cancer	5.37e-07	7.75e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CA—stomach cancer	5.02e-07	7.24e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—stomach cancer	4.91e-07	7.09e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPARG—stomach cancer	4.82e-07	6.95e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CA—stomach cancer	4.74e-07	6.84e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CA—stomach cancer	4.35e-07	6.27e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALB—stomach cancer	4.33e-07	6.25e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CA—stomach cancer	4.32e-07	6.23e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NOS3—stomach cancer	4.15e-07	5.98e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—stomach cancer	3.79e-07	5.47e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CA—stomach cancer	3.79e-07	5.46e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CA—stomach cancer	3.57e-07	5.15e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CA—stomach cancer	3.02e-07	4.36e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CA—stomach cancer	2.33e-07	3.37e-06	CbGpPWpGaD
